These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 27035622)

  • 21. Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein.
    Belda O; Targett-Adams P
    Virus Res; 2012 Dec; 170(1-2):1-14. PubMed ID: 23009750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor Ledipasvir.
    Cheng G; Tian Y; Doehle B; Peng B; Corsa A; Lee YJ; Gong R; Yu M; Han B; Xu S; Dvory-Sobol H; Perron M; Xu Y; Mo H; Pagratis N; Link JO; Delaney W
    Antimicrob Agents Chemother; 2016 Jan; 60(3):1847-1853. PubMed ID: 26824950
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.
    Li YP; Ramirez S; Humes D; Jensen SB; Gottwein JM; Bukh J
    Gastroenterology; 2014 Mar; 146(3):812-821.e4. PubMed ID: 24262279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiviral resistance and direct-acting antiviral agents for HCV.
    Aloia AL; Locarnini S; Beard MR
    Antivir Ther; 2012; 17(6 Pt B):1147-62. PubMed ID: 23188771
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resistance analysis and characterization of a thiazole analogue, BP008, as a potent hepatitis C virus NS5A inhibitor.
    Lin HM; Wang JC; Hu HS; Wu PS; Yang CC; Wu CP; Pu SY; Hsu TA; Jiaang WT; Chao YS; Chern JH; Yeh TK; Yueh A
    Antimicrob Agents Chemother; 2012 Jan; 56(1):44-53. PubMed ID: 22006008
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Direct-acting and host-targeting HCV inhibitors: current and future directions.
    Chatel-Chaix L; Germain MA; Götte M; Lamarre D
    Curr Opin Virol; 2012 Oct; 2(5):588-98. PubMed ID: 22959589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice.
    Shi N; Hiraga N; Imamura M; Hayes CN; Zhang Y; Kosaka K; Okazaki A; Murakami E; Tsuge M; Abe H; Aikata H; Takahashi S; Ochi H; Tateno-Mukaidani C; Yoshizato K; Matsui H; Kanai A; Inaba T; McPhee F; Gao M; Chayama K
    Gut; 2013 Jul; 62(7):1055-61. PubMed ID: 23322441
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase.
    Lemm JA; Liu M; Gentles RG; Ding M; Voss S; Pelosi LA; Wang YK; Rigat KL; Mosure KW; Bender JA; Knipe JO; Colonno R; Meanwell NA; Kadow JF; Santone KS; Roberts SB; Gao M
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3485-95. PubMed ID: 24733465
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of the Anti-HCV Activities of the New Cyclophilin Inhibitor STG-175.
    Gallay PA; Chatterji U; Bobardt MD; Long Z; Zhang S; Su Z
    PLoS One; 2016; 11(4):e0152036. PubMed ID: 27104614
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors.
    Chase R; Skelton A; Xia E; Curry S; Liu S; McMonagle P; Huang HC; Tong X
    Antiviral Res; 2009 Nov; 84(2):178-84. PubMed ID: 19747948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combinations of 2'-C-methylcytidine analogues with interferon-alpha2b and triple combination with ribavirin in the hepatitis C virus replicon system.
    Bassit L; Grier J; Bennett M; Schinazi RF
    Antivir Chem Chemother; 2008; 19(1):25-31. PubMed ID: 18610555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Andrographolide exerts anti-hepatitis C virus activity by up-regulating haeme oxygenase-1 via the p38 MAPK/Nrf2 pathway in human hepatoma cells.
    Lee JC; Tseng CK; Young KC; Sun HY; Wang SW; Chen WC; Lin CK; Wu YH
    Br J Pharmacol; 2014 Jan; 171(1):237-52. PubMed ID: 24117426
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current race in the development of DAAs (direct-acting antivirals) against HCV.
    De Clercq E
    Biochem Pharmacol; 2014 Jun; 89(4):441-52. PubMed ID: 24735613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitors.
    Welzel TM; Dultz G; Zeuzem S
    J Hepatol; 2014 Nov; 61(1 Suppl):S98-S107. PubMed ID: 25443350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase.
    Kukolj G; McGibbon GA; McKercher G; Marquis M; Lefèbvre S; Thauvette L; Gauthier J; Goulet S; Poupart MA; Beaulieu PL
    J Biol Chem; 2005 Nov; 280(47):39260-7. PubMed ID: 16188890
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A profiling study of a newly developed HCVcc strain PR63cc's sensitivity to direct-acting antivirals.
    Tao W; Gan T; Lu J; Zhong J
    Antiviral Res; 2017 Mar; 139():18-24. PubMed ID: 28025084
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens.
    Cento V; Nguyen THT; Di Carlo D; Biliotti E; Gianserra L; Lenci I; Di Paolo D; Calvaruso V; Teti E; Cerrone M; Romagnoli D; Melis M; Danieli E; Menzaghi B; Polilli E; Siciliano M; Nicolini LA; Di Biagio A; Magni CF; Bolis M; Antonucci FP; Di Maio VC; Alfieri R; Sarmati L; Casalino P; Bernardini S; Micheli V; Rizzardini G; Parruti G; Quirino T; Puoti M; Babudieri S; D'Arminio Monforte A; Andreoni M; Craxì A; Angelico M; Pasquazzi C; Taliani G; Guedj J; Perno CF; Ceccherini-Silberstein F
    PLoS One; 2017; 12(5):e0177352. PubMed ID: 28545127
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.
    Hofmann WP; Chung TL; Osbahr C; Susser S; Karey U; Mihm U; Welsch C; Lötsch J; Sarrazin C; Zeuzem S; Herrmann E
    Antivir Ther; 2011; 16(5):695-704. PubMed ID: 21817191
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons.
    Yu M; Corsa AC; Xu S; Peng B; Gong R; Lee YJ; Chan K; Mo H; Delaney W; Cheng G
    Antiviral Res; 2013 Nov; 100(2):439-45. PubMed ID: 24013001
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro combinations containing Tegobuvir are highly efficient in curing cells from HCV replicon and in delaying/preventing the development of drug resistance.
    Vliegen I; Paeshuyse J; Zhong W; Neyts J
    Antiviral Res; 2015 Aug; 120():112-21. PubMed ID: 26036224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.